Cargando…
Antibody Therapies for Large B-Cell Lymphoma
Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/ https://www.ncbi.nlm.nih.gov/pubmed/34040344 http://dx.doi.org/10.2147/BTT.S281618 |
_version_ | 1783696329760833536 |
---|---|
author | Novo, Mattia Santambrogio, Elisa Frascione, Pio Manlio Mirko Rota-Scalabrini, Delia Vitolo, Umberto |
author_facet | Novo, Mattia Santambrogio, Elisa Frascione, Pio Manlio Mirko Rota-Scalabrini, Delia Vitolo, Umberto |
author_sort | Novo, Mattia |
collection | PubMed |
description | Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface antigens that characterizes LBCL leads to a large umbrella of druggable targets. Monoclonal antibodies (mAbs) express their activity against lymphoma by targeting multiple tumor-specific antigens. This category consists of a number of molecules with different mechanisms of action, including naked mAbs, radioimmunoconjugates, antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies. In the last decade, apart from the well-known role of the anti-CD20 mAb rituximab, novel mAbs have led to remarkable steps forward in the treatment of R/R LBCL in monotherapy and combined with chemotherapy. Multiple studies are in development trying to bring these novel compounds into the frontline setting to empower the RCHOP effect or as alternative chemotherapy-free options for elderly/unfit patients. This review provides insight into antilymphoma mAbs, focused on the efficacy and safety of the main molecules approved or in development for LBCL andperspectives on the treatment of this disease. |
format | Online Article Text |
id | pubmed-8141264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81412642021-05-25 Antibody Therapies for Large B-Cell Lymphoma Novo, Mattia Santambrogio, Elisa Frascione, Pio Manlio Mirko Rota-Scalabrini, Delia Vitolo, Umberto Biologics Review Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface antigens that characterizes LBCL leads to a large umbrella of druggable targets. Monoclonal antibodies (mAbs) express their activity against lymphoma by targeting multiple tumor-specific antigens. This category consists of a number of molecules with different mechanisms of action, including naked mAbs, radioimmunoconjugates, antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies. In the last decade, apart from the well-known role of the anti-CD20 mAb rituximab, novel mAbs have led to remarkable steps forward in the treatment of R/R LBCL in monotherapy and combined with chemotherapy. Multiple studies are in development trying to bring these novel compounds into the frontline setting to empower the RCHOP effect or as alternative chemotherapy-free options for elderly/unfit patients. This review provides insight into antilymphoma mAbs, focused on the efficacy and safety of the main molecules approved or in development for LBCL andperspectives on the treatment of this disease. Dove 2021-05-18 /pmc/articles/PMC8141264/ /pubmed/34040344 http://dx.doi.org/10.2147/BTT.S281618 Text en © 2021 Novo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Novo, Mattia Santambrogio, Elisa Frascione, Pio Manlio Mirko Rota-Scalabrini, Delia Vitolo, Umberto Antibody Therapies for Large B-Cell Lymphoma |
title | Antibody Therapies for Large B-Cell Lymphoma |
title_full | Antibody Therapies for Large B-Cell Lymphoma |
title_fullStr | Antibody Therapies for Large B-Cell Lymphoma |
title_full_unstemmed | Antibody Therapies for Large B-Cell Lymphoma |
title_short | Antibody Therapies for Large B-Cell Lymphoma |
title_sort | antibody therapies for large b-cell lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/ https://www.ncbi.nlm.nih.gov/pubmed/34040344 http://dx.doi.org/10.2147/BTT.S281618 |
work_keys_str_mv | AT novomattia antibodytherapiesforlargebcelllymphoma AT santambrogioelisa antibodytherapiesforlargebcelllymphoma AT frascionepiomanliomirko antibodytherapiesforlargebcelllymphoma AT rotascalabrinidelia antibodytherapiesforlargebcelllymphoma AT vitoloumberto antibodytherapiesforlargebcelllymphoma |